相关实验视频
Updated: May 29, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.6K
减肥手术后的低血糖症:管理更新
1Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH aniraiqbal93@gmail.com.
Cleveland Clinic journal of medicine
|February 3, 2025
概括
腹腔外科手术可以改善与肥胖有关的疾病,但可能导致低血糖症. 本文回顾了当前和新兴的治疗方法,用于治疗腹腔外科手术后低血糖症 (PBH),这种疾病缺乏批准的药物.
科学领域:
- 代谢手术 代谢手术
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
背景情况:
- 减肥手术为肥胖患者提供了显著的健康益处,包括2型糖尿病和高血压的缓解.
- 一个值得注意的并发症是腹腔外科手术后低血糖症 (PBH),它可以在手术后几个月或几年表现出来.
- 目前,没有特定的药物被FDA批准用于管理PBH.
研究的目的:
- 审查可用和正在研究的治疗方案,以治疗腹腔外科手术后低血糖症.
- 为了提供对这种具有挑战性的并发症的治疗策略的概述.
主要方法:
- 对PBH管理研究的文献综述.
- 对当前临床指导方针和正在进行的研究进行分析.
主要成果:
- 讨论药理和非药理干预措施.
- 突出了针对PBH正在调查中的新兴疗法.
结论:
- 有效的PBH管理需要采用全面的方法.
- 需要进行进一步的研究,以开发针对PBH的批准和向疗法.
相关概念视频
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
SBAR II: Application of SBAR
4.3K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.3K
Oral Hypoglycemic Agents: Glinides
133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
Diabetes: Management and Pharmacotherapy
232
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
232

